Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Published byMarie-Christine Larrivée Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Clin. Oncol. doi: /nrclinonc"— Presentation transcript:

1 Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.85
Figure 2 Menin a major regulator of signalling in neuroendocrine neoplasms (NEN) Figure 2 | Menin a major regulator of signalling in neuroendocrine neoplasms (NEN). This figure highlights the points at which the tumour suppressor protein menin has been reported to mediate various pathways that are implicated in NEN development and/or progression. In the AKT/mTOR pathway, menin suppresses AKT-dependent proliferation in endocrine cells and in the Wnt signalling pathway, menin maintains physiological β-catenin levels. Menin also inhibits the activation of ERK48. ANGPT, angiopoietins; H3K4, methylation of lysine residue 4 of histone 3; H4R3, methylation of arginine residue 3 of histone 4; HDAC, histone deacetylase; PAI-1, plasminogen activator inhibitor-1; TFF1, trefoil factor 1. Kidd, M. et. al. (2016) Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Nat. Rev. Clin. Oncol. doi: /nrclinonc"

Similar presentations

SIRT1 (Sirtuin 1) A mamalian NAD+-dependent hitone deacetylase (HDAC) It deacetylates tumor suppressor.

SIRT1 (Sirtuin 1) A mamalian NAD+-dependent hitone deacetylase (HDAC) It deacetylates tumor suppressor.
Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 4 The mechanistic link between the epithelial-to-mesenchymal

Figure 4 The mechanistic link between the epithelial-to-mesenchymal
Figure 3 The contribution of the tumour microenvironment

Figure 3 The contribution of the tumour microenvironment
Figure 2 Signalling pathways and physiological domains that are

Figure 2 Signalling pathways and physiological domains that are
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Four nodes to target when inducing anti-tumour immunity

Figure 1 Four nodes to target when inducing anti-tumour immunity
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma
Figure 1 Classical and non-classical models of the cell cycle in RB1-proficient cells Figure 1 | Classical and non-classical models of the cell cycle in.

Figure 1 Classical and non-classical models of the cell cycle in RB1-proficient cells Figure 1 | Classical and non-classical models of the cell cycle in.
Figure 3 The cell cycle and the role of CDK4/6 inhibition

Figure 3 The cell cycle and the role of CDK4/6 inhibition

Similar presentations

Ads by Google